Skip to main content
. 2015 Mar 20;75(4):687–695. doi: 10.1136/annrheumdis-2014-207191

Figure 3.

Figure 3

(A) Study B (patients using tofacitinib) pneumococcal serotype-specific titre geometric mean fold rise (GMFR) from vaccination baseline and 95% CI at 35 days after vaccination, by exposure subgroup. (B) Study B (patients using tofacitinib) influenza antibody (haemagglutination inhibition) titre GMFR and 95% CI 35 days after vaccination, by exposure subgroup. +Tofacitinib withdrawn group; ++Tofacitinib continued group. BID, twice daily; DMARD, disease-modifying antirheumatic drug; GMFR, geometric mean fold rise; MTX, methotrexate.